Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Boehringer Ingelheim
Dow
Baxter
AstraZeneca

Last Updated: February 9, 2023

Details for New Drug Application (NDA): 205437


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 205437 describes OTEZLA, which is a drug marketed by Amgen Inc and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the OTEZLA profile page.

The generic ingredient in OTEZLA is apremilast. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the apremilast profile page.
Summary for 205437
Tradename:OTEZLA
Applicant:Amgen Inc
Ingredient:apremilast
Patents:11
Formulation / Manufacturing:see details
Pharmacology for NDA: 205437
Suppliers and Packaging for NDA: 205437
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OTEZLA apremilast TABLET;ORAL 205437 NDA Amgen Inc 55513-137 55513-137-28 1 BLISTER PACK in 1 CARTON (55513-137-28) / 28 TABLET, FILM COATED in 1 BLISTER PACK
OTEZLA apremilast TABLET;ORAL 205437 NDA Amgen Inc 55513-137 55513-137-50 500 TABLET, FILM COATED in 1 BOTTLE (55513-137-50)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Mar 21, 2014TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Apr 10, 2023
Regulatory Exclusivity Use:INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP
Regulatory Exclusivity Expiration:Dec 20, 2024
Regulatory Exclusivity Use:REVISIONS TO THE LABELING TO INCLUDE DATA FOR SUBJECTS WITH MILD TO MODERATE PLAQUE PSORIASIS, AND TO ALLOW FOR AN EXPANSION OF THE INDICATION
Regulatory Exclusivity Expiration:Jul 19, 2022
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE

Expired US Patents for NDA 205437

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 See Plans and Pricing See Plans and Pricing
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 See Plans and Pricing See Plans and Pricing
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Harvard Business School
Express Scripts
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.